The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed to reduce the overall risk of major adverse cardiovascular events (MACE).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,